Synopsys arrives at its September 30 earnings report on the back of a 10.6% weekly rally and the clearest bullish analyst consensus the stock has seen in years.
The options market captures the shift most vividly. The put/call ratio has collapsed to 0.89, nearly two standard deviations below its 20-day average of 1.11 — a reading that reflects an unusually high appetite for calls rather than protective puts. That's a sharp reversal from the elevated hedging that defined positioning through August and early September, when the PCR consistently held above 1.15. HSBC's upgrade to Buy on September 25, with a $700 target, arrived just as this rotation was accelerating. The borrow market adds no friction to the bullish picture: availability remains extraordinarily loose at nearly 6,900% — shares to borrow are effectively unlimited — and cost to borrow has drifted lower over the past month to just 0.38%. Short interest has crept up about 9% over the past week to 3.1% of the free float, but at that level it represents a modest and easily absorbed position rather than any meaningful short-side conviction.
The analyst debate has tilted sharply in one direction. HSBC's Buy at $700, Morgan Stanley's Overweight maintained at $500, and Wells Fargo's September 10 upgrade to Overweight have compressed the bearish camp considerably — BNP Paribas, which had been one of the last Underperform holdouts, stepped back to Neutral on September 24. The consensus mean target now sits at $554, implying roughly 30% upside from the current $425.76 price. Bulls point to Synopsys's dominant EDA franchise, AI-driven design tool adoption, and a consumption-based model shift that should generate compounding revenue synergies. Bears acknowledge the same strengths but flag valuation — the EV/EBITDA multiple has climbed to 22.3x, up about 1.3x on the week — and risks from customer concentration and competition. The factor score on analyst recommendation divergence ranks in the 100th percentile, meaning the Street's bullish tilt is essentially as extreme as it gets.
The most recent earnings print, in late August, produced a 13.7% single-session gain. That reaction shaped the current positioning: the stock spent September digesting the move, fell back toward the mid-$300s, then rebuilt sharply as the analyst upgrade cycle gathered momentum. Closest peer CDNS also rallied hard last week, gaining 15.3%, suggesting broader EDA sector tailwinds rather than SNPS-specific re-rating alone. Insider activity is worth noting: CEO Ghazi Sassine and Executive Chair Aart de Geus both executed planned sales under pre-arranged 10b5-1 programmes in September, with net insider selling running to roughly $38 million over 90 days. Pre-scheduled plans carry far less signalling weight than discretionary trades, but the net direction is worth flagging as a counterpoint to the analyst enthusiasm.
The print on September 30 will test whether Synopsys can justify a consensus that has swung from sceptical to near-unanimously bullish in under a month — and whether the momentum that carried the stock up 10% in a single week can survive contact with the actual numbers.
See the live data behind this article on ORTEX.
Open SNPS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
